Blackcrane Capital’s ClearPoint Neuro CLPT Stock Holding History

Blackcrane Capital’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-28,817	Closed	-$512K	–	15
2021 Q3	$512K	Buy	28,817 +1,164	+4%	+$21.8K	0.65%	14
2021 Q2	$528K	Sell	27,653 -13,613	-33%	-$263K	0.64%	14
2021 Q1	$872K	Buy	+41,266	New	+$883K	1.37%	13

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

GPC

Guardian Point Capital Charlottesville, Virginia $243M AUM 22.43% 1-Year Est. Return

Blackcrane Capital's CLPT Position: Q4 2021 in Review

Blackcrane Capital sold out of ClearPoint Neuro (CLPT) in Q4 2021, closing a stake of 28,817 shares — an estimated $512K sold.

Blackcrane Capital first reported a position in CLPT in Q1 2021 and held it in 3 quarters. The position peaked at $872K in Q1 2021. 67 funds tracked by Wall St. Rank hold CLPT as of Q4 2021.

Blackcrane Capital reported no remaining ClearPoint Neuro position as of Q4 2021 after selling out during the quarter.
Blackcrane Capital sold 28,817 ClearPoint Neuro shares in Q4 2021, an estimated $512K.
Blackcrane Capital first reported a position in ClearPoint Neuro in Q1 2021 and held it in 3 quarters.
Blackcrane Capital's ClearPoint Neuro position peaked at $872K in Q1 2021.
67 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q4 2021.

Based on Blackcrane Capital's 13F filing for Q4 2021, filed 14 Feb 2022.